XSpray Pharma AB (XSPRAY) - Total Liabilities

Latest as of June 2026: Skr173.68 Million SEK ≈ $18.69 Million USD

Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has total liabilities worth Skr173.68 Million SEK (≈ $18.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XSpray Pharma AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.

XSpray Pharma AB - Total Liabilities Trend (2015–2025)

This chart illustrates how XSpray Pharma AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see XSpray Pharma AB (XSPRAY) total assets.

XSpray Pharma AB Competitors by Total Liabilities

The table below lists competitors of XSpray Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
TAPEX INC KO:055490	Korea	₩39.20 Billion
Sequana Medical NV BR:SEQUA	Belgium	€53.74 Million
Akin Tekstil AS IS:ATEKS	Turkey	TL1.71 Billion
Lion Chemtech Co. Ltd KQ:171120	Korea	₩24.40 Billion
Nuveen New York Select Tax-Free Income Portfolio NYSE:NXN	USA	$658.55K
Intellicheck Mobilisa Inc NASDAQ:IDN	USA	$3.08 Million
Timberwell Bhd KLSE:7854	Malaysia	RM10.02 Million
Nice Information & Telecommunication Inc KQ:036800	Korea	₩822.77 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down XSpray Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XSPRAY net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.39	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.27	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XSpray Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XSpray Pharma AB (2015–2025)

The table below shows the annual total liabilities of XSpray Pharma AB from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr164.70 Million ≈ $17.72 Million	-4.94%
2024-12-31	Skr173.25 Million ≈ $18.64 Million	+141.12%
2023-12-31	Skr71.85 Million ≈ $7.73 Million	+144.30%
2022-12-31	Skr29.41 Million ≈ $3.17 Million	-5.59%
2021-12-31	Skr31.15 Million ≈ $3.35 Million	+37.13%
2020-12-31	Skr22.72 Million ≈ $2.44 Million	-15.73%
2019-12-31	Skr26.96 Million ≈ $2.90 Million	+150.32%
2018-12-31	Skr10.77 Million ≈ $1.16 Million	+87.17%
2017-12-31	Skr5.75 Million ≈ $619.17K	+6.78%
2016-12-31	Skr5.39 Million ≈ $579.83K	+100.45%
2015-12-31	Skr2.69 Million ≈ $289.27K	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$47.66 Million

Skr442.87 Million SEK

Market Cap Rank

#22177 Global

#413 in Sweden

Share Price

Skr9.34

Change (1 day)

-3.61%

52-Week Range

Skr9.28 - Skr63.40

All Time High

Skr258.00